Investor Presentaiton
Executive Summary
01
Following FDA clearance on March 30, 2023, and subsequent USA launch of the iTrack™ Advance in May 2023, Nova Eye Medical
Limited (Nova Eye) has driven USA glaucoma sales revenue to US$5.1m for 1H FY24, up 65% on pcp, selling through its own sales
team direct to US eye surgeons
02
Glaucoma products sales growth in the first half of FY24 was achieved despite market uncertainty during November and December
arising from proposed changes to reimbursement tabled by Medicare Administrative Contractors (MACS) to restrict reimbursement
coverage. The proposed changes were withdrawn on 29 December 2023 enabling future sales growth
03
Nova Eye sees significant near and medium-term opportunities to expand our glaucoma geographic sales footprint across the USA,
alongside strategic international markets. Focused product development and clinical evidence collation across the Glaucoma portfolio
will de-risk the Company from reimbursement changes
04
Announcement of capital raising of $8.0 million to capitalise on identified near-term growth opportunities in Glaucoma
n
nova-eye.com | 3View entire presentation